Overview

A Bioequivalence Study of Two Different Dosage Form of Genakumab

Status:
COMPLETED
Trial end date:
2025-01-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether Genakumab Injection is bioequivalent to Genakumab for Injection.
Phase:
PHASE1
Details
Lead Sponsor:
Changchun GeneScience Pharmaceutical Co., Ltd.
Treatments:
Injections
Powders
Solutions